Author/Authors :
Mostaan, Saied Department of Molecular Biology - Pasteur Institute of Iran - Tehran, Iran , Ghasemzadeh, Abbas Department of Molecular Biology - Pasteur Institute of Iran - Tehran, Iran , Sardari, Soroush Department of Medical Biotechnology - Biotechnology Research Center - Pasteur Institute of Iran - Tehran, Iran , Shokrgozar, Mohammad Ali National Cell Bank of Iran - Pasteur Institute of Iran - Tehran, Iran , Nikbakht Brujeni, Gholamreza Department of Microbiology and Immunology - Faculty of Veterinary Medicine - University of Tehran - Tehran, Iran , Abolhassani, Mohsen Department of Immunology - Pasteur Institute of Iran - Tehran, Iran , Ehsani, Parastoo Department of Molecular Biology - Pasteur Institute of Iran - Tehran, Iran , Asadi Karam, Mohammad Reza Department of Molecular Biology - Pasteur Institute of Iran - Tehran, Iran
Abstract :
Pasteurella multocida (P. multocida) is the highly contagious causative agent of a
broad range of diseases in animals as well as an occasional human pathogen. Economically
significant infections caused by P. multocida include avian fowl cholera,
rabbit snuffles, and hemorrhagic septicemia in cattle, goats and pigs. Chemotherapy
of pasteurellosis infections has some limitations, such as high cost of treatment, low efficacy,
and the possibility of therapy failure due to antibiotic resistance. Prophylactic
immunization offers a safe and effective preventive measure in case of zoonotic diseases.
Bacterins, live attenuated and some old traditional vaccines against pasteurellosis
remain in use today, beside their limitations. However, the past few years have
seen significant progress in research to identify modern, effective vaccine candidates,
but there is no new vaccine produced by new strategies. While scientists should struggle
with a lot of aspects to design vaccine producing strategies, this review shows how
pasteurellosis vaccine evolved and the limitations in its application which need to be
overcome.
